★★★★

UNION KOREA PHARM

Park Kwang-seok Acquires 9,455,845 Shares at 500 Won via Debt-to-Equity Swap Under Rehabilitation Plan, Stake at 15.87%: Massive Dilution Threatens Shareholder Value


  • Park Kwang-seok (manager at UNION KOREA PHARM) acquired 9,455,845 common shares at 500 won per share through a debt-to-equity swap as part of the rehabilitation plan, becoming a major shareholder with a 15.87% stake.
  • The debt-to-equity swap converts liabilities into equity, significantly increasing total outstanding shares to 59,573,136, thus diluting existing shareholders' ownership.
  • The acquisition price (500 won) is far below the current market price (2,725 won), effectively a deep discount issuance, raising concerns of downward price pressure due to increased supply.
  • Given the ongoing rehabilitation, further dilutive events or capital reductions may occur, posing substantial long-term risk.
  • [AI Overall Analysis]While this debt-to-equity swap may have been necessary for the company's rehabilitation, existing shareholders face unavoidable dilution and losses from the low-priced issuance. Caution is advised due to potential short-term stock price decline.

KOSDAQ Filing Information


  • Filing: Report on Ownership of Specific Securities by Executives and Major Shareholders
  • Company: UNION KOREA PHARM (080720)
  • Submission: Park Kwang-seok
  • Receipt: 05-26-2026